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Rationale: To evaluate bacterial colonization and the airway inflammatory response, and
its relationship to the frequency of exacerbation in patients with stable chronic
obstructive pulmonary disease (COPD).
Methods: Quantitative bacteriologic cultures, neutrophil elastase, myeloperoxidase
(MPO), tumor necrosis factor alpha (TNF-a) and interleukin (IL)-8 were measured in
bronchoalveoler lavage (BAL) in 39 patients with stable COPD [19 with frequent
exacerbation (X3/year), and 20 with infrequent] and in 18 healthy controls (10 smokers
and 8 non-smokers).
Results: BAL revealed the microorganisms with potential pathogenicity above the
established threshold (X103 cfu/ml) in 68.4% of patients with frequent exacerbation,
55% of infrequent exacerbation, 40% of smokers and 12.5% of non-smokers controls
(P ¼ 0:05). BAL MPO, IL-8 and TNF-a levels were found to be significantly higher in COPD as
compared to controls (P ¼ 0:001). However, only IL-8 level was significantly higher in COPD
patients with frequent exacerbation as compared to infrequent (P ¼ 0:001). Airway
bacterial load correlated with levels of airway inflammation markers in COPD (Po0:05).
Conclusion: The bacterial load and airway inflammation contributes to each other in
stable COPD. However, there is a link only between interleukine (IL)-8 and frequent
exacerbations. Clearly, the relationship between bacterial colonization, airway inflamma-
tion and frequent exacerbations is of major importance in understanding of the COPD
pathogenesis.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Exacerbations of chronic obstructive pulmonary disease
(COPD) are important causes of morbidity and mortality.1–3
Some patients with COPD are particularly susceptible to
develop frequent exacerbations,4 which are now being
recognized as an important feature of the natural history
of COPD, with important implications for health related
quality of life and hospital admission.5
The frequency of exacerbations increase with the severity
of COPD, however, the mechanism modulating exacerbation
frequency in patients with COPD are largely unknown. It has
recently been shown that COPD patients with frequent
exacerbations have higher sputum levels of IL-6 and IL-8 in
the stable state than patients with infrequent exacerba-
tions, suggesting that frequent exacerbations may be
associated with increased airway inflammation.6 Some
recent data also indicate that lower airway bacterial
colonization in the stable state modulates the character
and frequency of COPD exacerbations.4 However, definite
conclusions about the exact role of airway inflammation
and/or bacterial colonization in the modulating the exacer-
bation frequency in COPD are difficult to draw for a number
of reasons. First, previous studies investigated only one
aspect of the relationship between these factors: the
relationship of frequency of exacerbations with airway
inflammation or bacterial colonization. Furthermore, these
factors are uncertain whether these represent cause or
effect. Second, sputum was used in these studies instead of
bronchoalveoler lavage (BAL), which gives a better assess-
ment of small airways and alveolar inflammation and also
airway bacterial colonization.7,8 All of these may be
insufficient to obtain a full view. The knowledge of this
relationship may contribute to our further understanding of
the pathogenesis of COPD.
In accordance, in the current study we aimed to
concomitantly assess the relationships between frequency
of exacerbation and airway inflammation as well as bacterial
colonization by means of bronchoscopically retrieved BAL
samples in patients with stable COPD.
Materials and methods
Study protocol
The study protocol was approved by the Ethical Committee
of the Mersin University School of Medicine. Written
informed consent was obtained from all subjects before
enrolled into the study.
Study subjects
A prospective and observational study was undertaken.
Thirty-nine subjects with clinically stable mild-to-moderate
COPD, in accordance with GOLD guidelines9 were included in
the study. All COPD patients had a forced expiratory volume
in 1 s (FEV1)/forced vital capacity (FVC) ratio of o70% and
reversibility of o200ml or o12% in FEV1 after inhalation of
200 mg salbutamol. All COPD patients were ex-smokers. As
control group, 8 non-smoking and 10 smoking healthy, age-
matched volunteers were studied. All control subjects hadnormal spirometric values. All subjects were assessed
clinically and with a chest radiograph to ensure the absence
of other significant respiratory disease. In addition, all COPD
patients underwent high-resolution computed tomographic
(HRCT) investigations to characterize the nature of their
lung disease.
Study groups were as follows: Group I: Never smoker,
healthy control subjects (n ¼ 8), Group II: Current smoker,
healthy control subjects (n ¼ 10), Group III: COPD patients,
with frequent exacerbation (X3/previous year) (n ¼ 19),
and Group IV: COPD patients, with infrequent exacerbation
(o 3/previous year) (n ¼ 20).
Subjects with an exacerbation within the preceding
month, a recent respiratory tract infection within the last
6 weeks, clinical history of asthma, atopy, allergic disease,
bronchiectasis or other pulmonary disease, history of
systemic disease or malignancies, inhaled or systemic
corticosteroid therapy within 3 months and systemic
antimicrobial therapy within the last 4 weeks before entry
to the study were excluded.
Patients included in this study were selected from
patients with COPD seen in our outpatient’s clinic every 3
months over a 3 years period. Data relating to exacerbation
numbers were obtained retrospectively from records of our
outpatient’s clinic. Exacerbations were diagnosed according
to previous consensus definition, as follows, as a sustained
worsening of the patient’s condition from the stable state
and beyond normal day-to-day variations that is acute in
onset and may warrant additional treatment in a patient
with underlying COPD.10
Pulmonary function and CO diffusing tests
The pulmonary function tests including the DLCO measure-
ments were performed in the plant using computer-assisted
spirometry (Vmax22D, Sensor Medics, California, USA) in
accordance with the European Respiratory Society’s (ERS)
recommendations. Measurements of FVC, FEV1, FEV1/FVC
ratio, and maximal expiratory flow at 25–75% of VC
(FEF25–75%) were obtained and expressed as percent
predicted using normal values for adults of the European
Community for Steel and Coal.11 Carbon monoxide diffusing
tests were performed by the single-breath method, also in
accordance with ERS recommendations, to obtain a diffusing
capacity of CO (DLCO %).
12
Bronchoscopy and BAL
Fiberoptic bronchoscopy including BAL was performed in all
subjects. Prior to bronchoscopy, patients received premedi-
cation by intramuscular atropine (0.5mg) and topical
anesthesia by inhalation nebulized lignocaine (4ml, 2%
solution). Flexible bronchoscopy (Pentax EB-1830T3, Japan)
was performed transnasally. After inspection the bronchial
tree, the bronchoscope was wedged into a segmental
bronchus of the right middle lobe and 5 20ml sterile
saline solution was infused. Fluid was gently aspirated
immediately after the aliquot was introduced, the first
reaspirated portion was discarded, and remaining BAL fluid
collected in a sterile container. The total recovered BAL
fluid was recorded, and then was strained through a
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lavage sample was divided into three different aliquots for
the cytological examination, measurements of cytokine and
inflammatory mediators, and quantitative bacterial cul-
tures. The sample for cytokine and inflammatory mediators
was immediately centrifuged. Supernatants were removed
and frozen at 70 1C until measuring for mediators.
Measurement of airway inflammatory markers
Airway inflammation was evaluated by means of measure-
ments of neutrophil elastase (NE) and myeloperoxidase
(MPO) activities, and IL-8 and tumor necrosis factor alpha
(TNF-a) levels, and also albumin levels in BAL fluid.
BAL NE and MPO activity measurements: After BAL fluid
samples were homogenized, NE and MPO measurements
were performed. NE13 and MPO14 activity measurements
were assessed spectrophotometrically. Absorbances were
measured at 410 nm. Specific enzyme activity was calcu-
lated (Specific activity ¼ Absorbance at 410 nm/g protein).
BAL IL-8 and TNF-a measurement: Solid-phase Sandwich
Enzyme-Linked Immunosorbent Assay kits (Biosource Inter-
national, CA, USA) were used for assaying IL-8 and TNF-a
levels in the BAL supernatant. Measurements were made
according to the kits procedure with automatic micro-ELISA
machine (Tektime, BioMerieux, USA). All values were
expressed as pg/ml. The minimum detectable concentra-
tions were 5 pg/ml for IL-8 and 1.7 pg/ml for TNF-a.
Total protein measurement: Total protein content of BAL
samples was measured according to the method of Lowry
et al.15
Albumin measurement: BAL albumin was measured by
colorimetric assay using a commercially kit (Spin React;
Cod:1001020, lot: AL-72; Girona, Spain).
Permeability of the blood-airway lumen barrier: Plasma
protein leakage into the airway lumen was analyzed by
measuring albumin (Alb) in BAL fluid and paired serum
samples.16
Microbiological evaluation
BAL samples were serially diluted (dilutions of 1:10, 1:100,
and 1:1000). Diluted secretions were plated on blood,
chocolate, eosin–methylene and Sabouraud agar. Some
samples of BAL fluid were centrifuged and stained by the
Gram and Giemsa method. Additionally, epithel and neu-
trophil counts and morphology of microorganisms were
evaluated. Identification of microorganisms was performed
according to standard methods.17 Results of quantitative
cultures were expressed in colony-forming units per milli-
liter (cfuml). Bacterial agents were classified into poten-
tially pathogenic microorganisms (PPMs) or non-PPM.18,19 In
order to minimize the risk of dealing with contaminants,
only microorganisms with counts of X103 cfuml1 in BAL
fluid were regarded as significant.
Statistical analysis
Data analyses were performed with the Statistical Package
for the Social Science (SPSS 11.5, California, USA). Data are
expressed as means7standard deviation. w2 Tests were usedto compare the differences in the characteristics of two
groups. Data of independent two groups were compared
using Student t-test, whereas data of more than two groups
compared using one-way analysis of variance (ANOVA)
followed by Tukey HSD posthoc test to determine statistical
differences. Comparisons of two proportions between the
study and control groups were performed using the z-test.
Additionally, repeatability test was performed for serologic
measurements. Correlations were calculated by Spearman
correlation coefficient. Binary logistic regression analysis
(with Forward LR method) was performed to determine the
significant risk factors, which have a role for the increasing
in the exacerbation frequency. Statistical significance was
considered at Po0:05 level.
Results
Patients
Demographic characteristics of controls and patients with
COPD are given in Table 1. There were no statistical
differences among groups with regard to age, sex, cigarette
consumption or body mass index (BMI) (Table 1).
The mean predicted FEV1 was 70.6712%, with a range
from 50% to 88%. Therefore, all COPD patients can be
classified as suffering from mild-to-moderate COPD accord-
ing to GOLD criteria.14 Functional data of controls and COPD
patients are summarized in Table 2.
Bronchoscopy was well tolerated by all subjects without
adverse effects.
During BAL procedure, the mean recovery of the injected
fluid was similar among groups, and found to be 37.976.5ml
in COPD patients with frequent exacerbation, 38.7711ml in
COPD patients with infrequent exacerbation, 40.7710.3ml
in the smokers control subjects, 41.6712.7ml the non-
smokers control group (P40:05).
Results of airway inflammatory markers
NE and MPO activities of BAL were found to be higher in the
COPD patients with frequent exacerbations as compared to
COPD patients with infrequent exacerbations, but the
difference was not statistically significant (Fig. 1a and b).
BAL IL-8 and TNF-a levels were found to be higher in the
COPD patients with frequent exacerbations as compared to
COPD patients with infrequent exacerbations, but the
difference was statistically significant for only IL-8 levels
(P ¼ 0:001) (Fig. 1c and d).
Serum/BAL albumin leakage was 1.170.9 in COPD
patients with frequent exacerbation, 0.8970.3 in patients
with infrequent exacerbations, 0.4170.3 in the smokers
control group and 0.2970.5 in the non-smokers control
group (P ¼ 0:001).
Microbiological results
BAL revealed the presence of microorganisms with potential
pathogenity above the established threshold (X103 cfu/ml)
in 13 (68.4%) of COPD patients with frequent exacerbations,
in 11 (55%) of COPD patients with infrequent exacerbations,
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Table 2 Pulmonary function tests and arterial blood gases.
Control COPD
Non-smoker Smoker Frequent exacerbation Infrequent exacerbation
FVC (% predicted) 109.678.7 99.2717.7 89.1713.5 96.7712.9
FVC (l) 4.571.4 3.970.7 3.370.7 3.670.7
FEV1 (% predicted) 107.176.3 95716.2 65.8712.8 70.5712
FEV1 (l) 3.670.9 3.170.,5 1.970.5 2.170.5
FEV1/FVC 8175.2 78.574.1 58.577.2 60.774.7
FEF25–75 (% predicted) 96.3719.8 75.3718.1 25.178.6 32.879.9
DLCO (% predicted) 104.3724 107.2713.2 80.4726.8 85.8732.1
SaO2 (%) 97.471.1 96.871.3 95.371.4 95.771.1
PaO2 (mmHg) 94.6710.6 8678.5 78.678.4 81.776.9
PaCO2 (mmHg) 37.373.8 3772.3 38.273.6 36.573.6
pH 7.4270.38 7.4270.01 7.4070.02 7.4170.02
HCO3 2471.6 23.471.1 23.771.9 2371.9
Data were presented as mean7SD.
Table 1 Characteristics of controls and patients with COPD.
Control COPD
Non-smoker Smoker Frequent
exacerbation
Infrequent
exacerbation
Subjects (n) 8 10 19 20
Sex
Male 6 9 17 18
Female 2 1 2 2
Age 45.674.9 50.274.5 58.8477.7 58.5577.7
BMI (kg/m2) 26.9274.3 27.774.9 23.6373.9 25.4774.5
Cigarette consumption (pack/years)* — 37.7713.3 50.26722.2 46.20722.1
Number of exacerbation
(previous year)*
— — 5.7374.1 1.170.8
(Mean7SD).
M. Tumkaya et al.732and in 4 (40%) of smokers controls and in 1 (12.5%) of non-
smokers controls (P ¼ 0:05). Overall colonization rates were
61.5% (24 out of 39) in all COPD patients and 27.8% (5 out of
18) in all controls (P ¼ 0:018) (Table 3). Total 9 of 24
colonized COPD patients, 4 of the 13 colonized COPD
patients with frequent exacerbation and 5 of the 11
colonized COPD patients with infrequent exacerbations,
had multiple organisms. Three COPD patients had triple
infection, and 6 had double. Neisseria species being the
most common microorganism isolated followed by both
Streptococcus spp., and Haemophilus influenzae in multiple
infections of COPD patients.
The mean BAL neutrophil cell count was found to be
higher in COPD patients with frequent and infrequent
exacerbation as compared to non-smoking controls (Fig. 2).
COPD patients have significantly higher total bacterial
load as compared to the controls (P ¼ 0:017). However,
there was no statistically significant difference between
COPD patients with frequent exacerbations and patientswith infrequent exacerbations with respect to total bacter-
ial load (Fig. 3).The relationship of bacterial colonization, airway
inflammatory markers and exacerbation frequency
Bacterial load were positively correlated with airway
inflammatory markers in patients with COPD. Correlation
coefficient was strong especially for IL-8 (r ¼ 0:52,
P ¼ 0:009) (Fig. 4).
In subjects with COPD, increased serum/BAL albumin
leakage was strongly correlated with increased BAL neu-
trophil counts (r ¼ 0:47, P ¼ 0:02) and airway bacterial load
(r ¼ 0:41, P ¼ 0:03). These findings suggest a possible causal
relationship between lung vascular permeability and neu-
trophil numbers in subjects with COPD.
Logistic regression analysis was performed to determine
the significant predictive factors for the frequent/infre-
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Figure 1 Levels of inflammatory markers in BAL fluid. Horizantal bars represent mean795% confidence interval values: (a) NE
activity (P ¼ 0:028 with ANOVA, and P ¼ 0:034 with Tukey posthoc test), (b) MPO activity (P ¼ 0:005 with ANOVA, and P ¼ 0:015,
P ¼ 0:024 with Tukey posthoc test), (c) IL-8 levels (P ¼ 0:001 with ANOVA, and P ¼ 0:001 with Tukey posthoc test) and (d) TNF-a
levels (P ¼ 0:012 with ANOVA, and P ¼ 0:05, P ¼ 0:024 with Tukey posthoc test).
Table 3 Isolated microorganisms in BAL fluid (X103).
Control (n ¼ 18) COPD (n ¼ 39)
Non-smoker
(n ¼ 8)
Smoker
(n ¼ 10)
Frequent
exacerbation
(n ¼ 19)
Infrequent
exacerbation
(n ¼ 20)
Streptococcus pneumoniae 0 0 0 2
Haemophilus influenzae 0 0 2 0
Moraxella catarrhalis 0 0 1 0
Staphylococcus aureus 0 0 1 0
Streptococcus spp. 1 4 10 10
Neisseria species 0 0 3 2
Coagulase () Staphylococcus 0 0 0 1
Haemophilus spp. 1 0 0 1
Total 1 (12.5%) 4 (40%) 13 (68.4%) 11 (55%)
Total number of subjects in whom at least one microorganism was isolated in BAL.
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Figure 2 Neutrophil counts in BAL fluid. Neutrophil count
values represent the number of neutrophil cellsml1 of
recovered lavage fluid. Horizontal bars represent mean795%
confidence interval values (P ¼ 0:025 with ANOVA, and
P ¼ 0:026, P ¼ 0:044 with Tukey posthoc test).
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Figure 3 Total bacterial load in BAL fluid. Horizontal bars
represent mean795% confidence interval values (P ¼ 0:049
with ANOVA, and P ¼ 0:039 with Tukey posthoc test).
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Figure 4 Correlation between BAL total bacterial load and BAL
IL-8 levels in COPD patients. Total bacterial load were positively
correlated with IL-8 levels (r ¼ 0:52, P ¼ 0:009).
M. Tumkaya et al.734quent exacerbations in COPD patients. This analysis showed
that 1 pg/ml of increase in BAL IL-8 level increased the risk
of frequent exacerbations 1 fold (P ¼ 0:022, Exp B ¼ 1:007,
CI %95: 1.001–1.012), and per hundred milliliter decreases in
FEV1 increased the risk of frequent exacerbations 1 fold
(P ¼ 0:05, Exp B ¼ 0:099, CI %95: 0.010–1.012), when the
exacerbation frequency was the dependent variable, and
smoking, total bacterial load, FEV1 and airway inflammatorymarkers were independent variables. There was not a
significant relationship between airway colonization and
exacerbation frequency.Discussion
In the present study, we found that subjects with COPD who
do not currently smoke have airways inflammation as shown
by a significant increase in IL-8, TNF-a and MPO levels, and
protein leakage, and total bacterial load compared with
healthy controls. Also, airway bacterial load was positively
correlated with inflammation markers in BAL in patients
with COPD. Among airway inflammatory markers, there is a
link only between IL-8 and frequent exacerbations in COPD
patients. However, a significant relationship was not found
between airway colonization and exacerbation frequency in
COPD patients.
COPD is characterized predominantly by neutrophilic
airway inflammation and this is thought to represent an
exaggerated response to tobacco smoking. Several studies
showed increased IL-8 levels in induced sputum and BAL in
patients with COPD compared with smokers without
COPD.20–22 There is also evidence that bacterial products
affect neutrophil migration and may independently mod-
ulate airway inflammation.23,24 Bacterial colonization of
distal airways is frequently found in patients with stable
COPD.4,24,25 Reported bacterial colonization rate in stable
COPD patients changes from 33% to 100%. Important causes
of this wide range are using different airway samples
(sputum, protected brush, BAL) and the risk factors
influencing bacterial colonization (smoking, airway obstruc-
tion severity, airway inflammation).26 In this study, we
evaluated airway colonization using BAL samples. Accord-
ingly, overall airway bacterial colonization rates were 61.5%
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all controls. Some patients (total 9 of 24 colonized COPD
patients) are infected two or more microorganism. Neisseria
species being the most common microorganism isolated
followed by both Streptococcus spp., and H. influenzae in
multiple infections of COPD patients. The bacterial coloni-
zation rate and bacterial species that we isolated are similar
to those found in many prior studies of sputum and lower
airway bacteriology.26 The significance of bacterial coloni-
zation of the bronchial tree in terms of the development and
progression of airway inflammation is not precisely known.
Nevertheless, there is evidence that inflammatory response
to bacterial pathogens is an important contributor to the
damage of epithelial surfaces, thus promoting further
bronchial colonization.4,25,27 Soler et al.25 showed that
bacterial colonization in the distal airways is associated with
increased polymorphonuclear cells and TNF-a in BAL fluid
from patients with COPD. Patel et al.4 found that the
bacterial count was related to the sputum level of IL-8. Hill
et al. demonstrated that increasing airway bacterial load
was strongly related to several markers of inflammation in
airway secretions, including sputum MPO and IL-8 levels, as
well as leukocyte elastase activity.16 In the present study,
we have again confirmed that higher airway bacterial load is
associated with greater airway inflammation in terms of BAL
IL-8, TNF-a and MPO levels and also protein leakage in
patients with COPD. Additionally, in subjects with COPD,
increased serum/BAL albumin leakage was strongly corre-
lated with increased BAL neutrophil counts. These findings
suggest a possible causal relationship between lung vascular
permeability and neutrophil numbers in subjects with COPD,
and that the bacterial load and airway inflammation
contributes to each other in patients with stable COPD.
Recent data indicates that some patients with COPD
develop frequent exacerbations, and recurrent exacerba-
tions may be associated with increased airway inflamma-
tion, although it is uncertain whether this represents cause
or effect. Bhowmick et al.28 showed that patients with
frequent exacerbations had heightened airway inflammation
when stable as measured by induced sputum IL-6 and IL-8
levels. The interpretation of these results is far from clear as
many factors may influence inflammation in the airways.
These include the severity of airflow obstruction, smoking
status, bronchiectasis, bacterial colonization, treatment
with inhaled corticosteroids, and the exacerbation itself.6
Although, Bhowmick et al.28 postulated that this might be
due to the load of bacteria in the lower airways, there was
no information concerning current smoking status, bacterial
colonization or use of inhaled corticosteroids, all of which
might have influenced the results. It is possible that
frequent exacerbations may have a continuing influence on
bronchial inflammation even in the stable clinical state. On
the other hand, in the study of Gompertz et al.6 in which the
relationship between airway inflammation and the fre-
quency of exacerbations was examined in patients with
COPD, authors found no differences in any of inflammation
markers including IL-8 between the patients with frequent
and infrequent exacerbations. There were also no differ-
ence in the severity of airflow obstruction, current smoking
status, or in the prevalence or degree of airway coloniza-
tion, all of which are known to influence airway inflamma-
tion. They concluded that there are several clinical featuresthat directly influence airway inflammation in COPD, and
when these were carefully controlled for patients with more
frequent reported exacerbations did not have significantly
greater bronchial inflammation.6 In the present study,
among airway inflammatory markers, there is a link only
between IL-8, a neutrophil chemoattractant, and frequent
exacerbations in COPD patients. The difference in the
results of inflammation or colonization between the
different studies may be related to several unreported,
undetected, or uncontrolled factors for clinical differences
between the groups of patients. Thus, we did not include
subjects with bronchiectasis or inhaled or systemic corti-
costeroid therapy in the study in order to study airway
inflammation and colonization of COPD as well as possible.
Previous studies have indicated that, although clinically
indistinguishable, patients with bronchiectasis have evi-
dence of increased airway inflammation and colonization,
and airway inflammation and colonization may be altered by
the nature of the disease (COPD or bronchiectasis).29 One of
the other well-known confounding factor that influence the
airway inflammation, colonization and/or exacerbation
frequency, is steroid using. Although, inhaled corticosteroids
do not modify disease progression in COPD, there is
increasing evidence that they reduce the number of
exacerbations in COPD.30 Corticosteroids are also known to
have some beneficial effects on bronchial inflammation,
including reducing airway neutrophilia31 and reducing
protein leakage.6 On balance, therefore, it is likely that
steroids do alter airway inflammation and again this should
be born in mind when assessing the results of patient
studies. Moreover, the result of most studies indicated that
inhaled steroids were prescribed to patients with higher
inflammatory activity, thus, this factor could effect the
difference in COPD patients as compared to controls.6,25 In
this study, additionally, logistic regression analysis was
performed to determine the other possible significant risk
factors which had a role in the increasing in the exacerba-
tion frequency in COPD patients. Logistic regression analysis
of the data from this study showed that BAL IL-8 level and
severity of airflow obstruction were predictive significant
risk factors for frequent exacerbation, however, it did not
show a significant influence of smoking, total bacterial load,
and airway inflammatory markers except IL-8 on exacerba-
tion frequency. Patel et al.4 found that the presence of
bacterial colonization in the stable state was associated
with increased exacerbation frequency, and patients with
colonization had longer and thus more severe exacerba-
tions. In the present study, unlike as Patel et al.,4 we did not
find a significant relationship between airway colonization
and exacerbation frequency in COPD patients. This might be
a surprising result. As we found that patients with a history
of frequent exacerbations had increased airway inflamma-
tion in terms of BAL IL-8 level, and airway bacterial load
were positively correlated with inflammation markers in
BAL, bacterial colonization might be expected to be an
important factor for exacerbation frequency.
We believe that the superiority of our study is that it
examines BAL, while most previous studies have examined
sputum.4,6,25,26 BAL should give a better assessment of small
airways and alveolar inflammation, and also more reliable
for assessment of airway bacterial colonization than
sputum.7,8 However, generally, there are some problems
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BAL fluid samples. There is a risk of contamination of
bacteria during the FOB and BAL procedure, because some
bacteria species are normal naso-oro-pharyngeal flora, non-
quantitative culture may be confusing, because it cannot
confirm a lower respiratory source for these isolates. In
order to minimize the risk of dealing with contaminants, we
used quantitative cultures of BAL fluid samples as the
gold standard, and only microorganisms with counts of
X103 cfuml1 in BAL fluid were regarded as significant. An
another problem with BAL fluid samples is the recovery and
dilution of sample material. The analysis of protein levels in
BAL fluid is complicated by variable dilution of the epithelial
lining fluid (ELF) by the BAL procedure, which may differ
between patients and within patients. One approach to take
into account the variable dilution, proposed by some
authors, is to use a correction factor based on concentra-
tions of a reference protein (e.g. albumin or urea) in serum
and BAL fluid to calculate protein levels in ELF.32 It is also
reported that in the analysis of lung proteins recovered by
lavage, some of recovered proteins depend on lavage
volume. Larger volumes will add more protein but not alter
protein ratios.33 In this study, total protein content of BAL
fluid was measured, and used as a marker of ELF dilution
allowing the calculation of an apparent ELF volume and
adjusted protein content. To our best knowledge, this is the
first study concomitantly assessing the relationship between
the frequency of exacerbation and airway inflammation as
well as bacterial colonization by means of bronchoscopically
retrieved BAL samples in patients with stable COPD. Our
study enriched the findings of two previous studies using
sputum samples in their evaluations; the first is the study of
Gompertz et al.,6 which investigated the relationship
between exacerbation frequency and bronchial inflamma-
tion, and the second is the study of Patel et al.,4 which
evaluated the relationship between bacterial colonization
and the exacerbation frequency in COPD patients.
In conclusion, the bacterial load and airway inflammation
contributes to each other in patients with stable COPD.
However, there is a link only between IL-8 and frequent
exacerbations. Clearly, the relationship between bacterial
colonization, bronchial inflammation and frequent exacer-
bations is of major importance in understanding of the
pathogenesis of COPD.
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